Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.00 Insider Own35.23% Shs Outstand58.95M Perf Week1.89%
Market Cap64.90M Forward P/E- EPS next Y-1.50 Insider Trans16.15% Shs Float38.92M Perf Month5.88%
Income-116.39M PEG- EPS next Q-0.36 Inst Own27.40% Short Float1.77% Perf Quarter-10.00%
Sales7.59M P/S8.55 EPS this Y17.18% Inst Trans-2.16% Short Ratio1.38 Perf Half Y-14.96%
Book/sh2.28 P/B0.47 EPS next Y7.33% ROA-49.32% Short Interest0.69M Perf Year-28.48%
Cash/sh2.53 P/C0.43 EPS next 5Y- ROE-64.20% 52W Range0.69 - 2.29 Perf YTD-13.60%
Dividend Est.- P/FCF- EPS past 5Y-72.78% ROI-72.10% 52W High-52.84% Beta1.85
Dividend TTM- Quick Ratio8.32 Sales past 5Y0.00% Gross Margin54.67% 52W Low56.52% ATR (14)0.10
Dividend Ex-Date- Current Ratio8.32 EPS Y/Y TTM8.48% Oper. Margin-1445.17% RSI (14)56.85 Volatility7.85% 12.35%
Employees63 Debt/Eq0.20 Sales Y/Y TTM521.38% Profit Margin-1534.11% Recom1.00 Target Price4.12
Option/ShortYes / Yes LT Debt/Eq0.18 EPS Q/Q-9.63% Payout- Rel Volume0.54 Prev Close1.04
Sales Surprise152.00% EPS Surprise-18.34% Sales Q/Q106.39% EarningsMay 09 AMC Avg Volume498.31K Price1.08
SMA2018.93% SMA5010.06% SMA200-2.47% Trades Volume271,375 Change3.85%
Date Action Analyst Rating Change Price Target Change
Sep-14-22Initiated Berenberg Buy $12
Oct-20-21Resumed Cowen Outperform
Jun-24-21Initiated H.C. Wainwright Buy $35
Nov-03-20Initiated Piper Sandler Overweight $50
Nov-03-20Initiated Jefferies Buy $36
Nov-03-20Initiated Goldman Buy $45
Nov-03-20Initiated Cowen Outperform
May-23-24 05:15PM
May-22-24 04:30PM
May-21-24 08:15AM
May-16-24 09:35AM
May-09-24 10:55PM
05:45PM Loading…
Apr-24-24 04:01PM
Mar-27-24 12:00PM
Mar-21-24 01:53PM
Mar-07-24 04:05PM
Mar-05-24 04:44PM
Feb-27-24 04:05PM
Jan-25-24 08:00AM
04:06PM Loading…
Dec-18-23 04:06PM
Dec-04-23 08:00AM
Nov-27-23 04:05PM
Nov-13-23 05:25PM
Nov-02-23 04:05PM
Oct-27-23 08:00AM
Oct-13-23 12:30PM
Oct-04-23 04:05PM
Aug-17-23 08:00AM
Aug-08-23 05:50PM
Jul-19-23 07:27AM
Jun-06-23 08:00AM
04:05PM Loading…
Jun-01-23 04:05PM
May-12-23 07:00AM
May-10-23 05:35PM
Apr-24-23 04:05PM
Apr-18-23 02:24PM
Apr-11-23 04:05PM
Mar-15-23 04:05PM
Feb-28-23 04:05PM
Jan-09-23 09:25AM
Dec-20-22 10:28AM
Dec-12-22 09:35AM
Dec-11-22 10:00AM
Dec-07-22 04:05PM
Nov-22-22 04:05PM
Nov-09-22 12:04PM
Nov-08-22 04:10PM
Oct-12-22 04:04AM
Sep-06-22 04:05PM
Aug-22-22 11:33AM
Aug-16-22 04:05PM
Aug-09-22 09:55AM
Aug-04-22 04:05PM
Jul-25-22 08:48AM
Jul-10-22 10:27AM
Jul-08-22 12:00PM
Jun-10-22 03:04AM
Jun-01-22 04:05PM
May-22-22 08:04AM
May-17-22 07:00AM
May-12-22 10:23AM
May-06-22 12:23PM
May-04-22 04:05PM
Apr-08-22 01:07PM
Mar-08-22 05:08PM
Mar-01-22 07:00AM
Feb-24-22 04:05PM
Feb-01-22 04:05PM
Jan-31-22 01:45PM
Dec-17-21 08:00AM
Dec-09-21 10:15AM
Dec-06-21 07:00AM
Nov-29-21 07:00AM
Nov-24-21 07:00AM
Nov-11-21 04:05PM
Nov-09-21 04:10PM
Nov-08-21 04:44PM
Nov-04-21 07:00AM
Oct-11-21 09:41AM
Oct-05-21 12:17PM
Sep-30-21 04:36PM
Sep-14-21 08:00AM
Sep-07-21 07:00AM
Aug-12-21 04:05PM
Jul-27-21 05:36PM
Jul-12-21 04:56AM
May-26-21 08:00AM
May-25-21 08:00AM
May-11-21 04:05PM
May-06-21 08:00AM
Apr-11-21 05:53AM
Apr-10-21 08:30AM
Mar-31-21 11:25AM
Mar-26-21 08:00AM
Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISCHOFBERGER NORBERT WPRESIDENT & CEOJun 12 '24Buy1.24881,9131,096,0417,375,616Jun 12 07:23 PM
BISCHOFBERGER NORBERT WPRESIDENT & CEOJun 11 '24Buy1.09744,308814,5716,493,703Jun 12 07:23 PM
BISCHOFBERGER NORBERT WPRESIDENT & CEOJun 10 '24Buy0.881,378,9011,208,4695,749,395Jun 12 07:23 PM
Frisbee AllisonSR VP, CORP OPERATIONS & LEGALFeb 21 '24Sale1.0512,10512,757204,510Feb 23 08:04 PM
Lin Charles YSR VP, RESEARCH & DEVELOPMENTFeb 21 '24Sale1.0512,03612,685234,603Feb 23 08:07 PM
Olek Elizabeth ASR VP, CLINICAL SCIENCEFeb 21 '24Sale1.057,3687,765193,275Feb 23 08:12 PM
DiMartino JorgeChief Medical Officer & VPJan 04 '24Sale1.1812,00914,214315,246Jan 05 06:27 PM
Kosacz BarbaraCOO & General CounselJan 04 '24Sale1.1810,67612,636928,966Jan 05 06:26 PM
Dinsmore ChristopherChief Scientific OfficerJan 04 '24Sale1.187,3668,718260,969Jan 05 06:30 PM
DiMartino JorgeChief Medical Officer & VPDec 12 '23Sale1.3017,36722,664327,255Dec 13 04:09 PM
Dinsmore ChristopherChief Scientific OfficerDec 12 '23Sale1.3010,03213,092268,335Dec 13 04:10 PM
BISCHOFBERGER NORBERT WPresident & CEONov 17 '23Buy1.0897,935106,1622,540,665Nov 17 05:41 PM
BISCHOFBERGER NORBERT WPresident & CEONov 16 '23Buy1.00262,433261,5142,442,730Nov 17 05:41 PM
BISCHOFBERGER NORBERT WPresident & CEONov 15 '23Buy0.801,370,6881,102,7182,180,297Nov 17 05:41 PM
DiMartino JorgeChief Medical Officer & VPJul 06 '23Sale1.7510,81818,956344,622Jul 07 04:07 PM
Al-Wakeel Yasir B.Chief Financial OfficerJul 06 '23Sale1.759,61716,852346,102Jul 07 04:06 PM
Dinsmore ChristopherChief Scientific OfficerJul 06 '23Sale1.756,63411,625278,367Jul 07 04:08 PM